Table 4 Proteinuria incidence between third and twelve post-transplant months per MYH9 risk variant in additive, recessive and dominant models: Data for variables with P < 0.05 are shown in bold

rs11089788

AA

55

11.1

13.0

27.8

–

AC

105

15.5

1.47

0.54–4.01

0.629^ACvAA

13.5

1.04

0.39–2.76

1.000 ^ACvAA

26.0

0.91

0.43–1.92

0.850 ^ACvAA

CC

47

17.0

1.11

0.44–2.82

0.814 ^CCvAC

17.0

1.32

0.51–3.40

0.621 ^CCvAC

30.4

1.24

0.58–2.69

0.690 ^CCvAC

rs11089788

AA

55

11.1

–

13.0

27.8

–

AC + CC

152

16.0

1.52

0.59–3.96

0.503 ^CvAA

14.6

1.14

0.46–2.85

1.000 ^CvAA

27.4

0.98

0.49–1.97

1.000 ^CvAA

rs11089788

CC

47

17.0

–

17.0

–

30.4

–

AA+AC

160

14.0

1.26

0.52–3.05

0.609 ^CCvA

13.3

1.34

0.55–3.25

26.6

1.21

0.58–2.48

0.707 ^CCvA

rs136211

AA

21

9.5

–

9.5

–

25.0

–

AG

91

8.8

0.92

0.18–4.66

1.000 ^AGvAA

12.1

1.31

0.27–6.39

1.000 ^AGvAA

21.1

0.80

0.26–2.49

0.766 ^AGvAA

GG

95

21.7

2.88

1.20–6.94

0.023 ^GGvAG

17.2

1.51

0.66–3.46

0.406 ^GGvAG

34.4

1.96

1.01–3.83

0.067 ^GGvAG

rs136211

AA

21

9.5

–

9.5

–

25.0

–

AG + GG

186

15.3

1.72

0.38–7.78

0.745 ^GvAA

14.7

1.63

0.36–7.42

0.745 ^GvAA

27.8

1.15

0.40–3.34

1.000 ^GvAA

rs136211

GG

95

21.7

–

17.2

–

21.8

–

AG + AA

112

8.9

2.83

1.25–6.41

0.016 ^GGvA

11.6

1.58

0.72–3.49

0.315 ^GGvA

34.4

1.88

1.00–3.56

0.056 ^GGvA

rs3752462

CC

112

15.4

–

15.3

–

29.0

–

CT

79

14.1

0.90

0.39–2.04

0.838 ^CTvCC

12.8

0.81

0.35–1.88

0.678 ^CTvCC

26.9

0.90

0.47–1.73

0.869 ^CTvCC

TT

16

12.5

0.87

0.17–4.37

1.000 ^TTvCT

12.5

0.97

0.19–4.92

1.000 ^TTvCT

20.0

0.68

0.17–2.64

0.752 ^TTvCT

rs3752462

CC

112

15.4

–

15.3

–

29.0

–

CT + TT

95

13.8

0.88

0.40–1.92

0.844 ^TvCC

12.8

0.81

0.36–1.79

0.689 ^TvCC

25.8

0.85

0.46–1.59

0.637 ^TvCC

rs3752462

TT

16

12.5

–

12.5

–

20.0

–

CC + CT

191

14.9

0.82

0.18–3.79

1.000^TTvC

14.3

0.86

0.18–3.98

1.000 ^TTvC

28.1

0.64

0.17–2.36

0.764 ^TTvC

rs5756168

CC

3

33.3

–

33.3

–

33.3

–

CT

39

5.1

0.11

0.01–1.76

0.204 ^CTvCC

7.7

0.17

0.01–2.42

0.265 ^CTvCC

18.4

0.45

0.04–5.71

0.488 ^CTvCC

TT

165

16.7

3.70

0.84–16.28

0.077 ^TTvCT

15.3

2.17

0.62–7.61

29.6

1.86

0.76–4.52

0.224 ^TTvCT

rs5756168

CC

3

33.3

–

33.3

–

33.3

–

CT + TT

204

14.4

0.34

0.03–3.84

0.359 ^TvCC

13.9

0.32

0.03–3.67

0.369 ^TvCC

27.4

0.75

0.07–8.50

1.000 ^TvCC

rs5756168

TT

165

16.7

–

15.3

–

29.6

–

CC + CT

42

7.1

2.60

0.75–9.03

0.147 ^TTvC

9.5

1.72

0.56–5.25

0.458 ^TTvC

19.5

1.73

0.74–4.03

0.241 ^TTvC

rs2239784

CC

187

15.2

–

15.1

–

28.7

–

CT

20

10.0

0.62

0.14–2.82

0.744 ^CTvCC

5.0

0.29

0.04–2.29

0.320 ^CTvCC

15.8

0.46

0.13–1.66

0.289 ^CTvCC

TT

0

–

–

–

rs2239784

CC

187

15.2

–

–

28.7

–

CT + TT

20

10

0.62

0.14–2.82

0.744 ^TvCC

–

TvCC

15.8

0.46

0.13–1.66

0.289 ^TvCC

rs2239784

TT

0

–

–

–

CC + CT

207

14.7

–

–

–

rs4821480

GG

1

0

–

0

–

0

–

GT

27

11.1

–

1.000 ^GTvGG

18.5

–

1.000 ^GTvGG

33.3

–

TT

179

15.4

1.50

0.41–5.15

0.773 ^TTvGT

13.6

0.69

0.24–2.00

0.553 ^TTvGT

26.6

0.72

0.30–1.73

0.490 ^TTvGT

rs4821480

GG

1

0

–

0

–

0

–

GT + TT

206

14.8

–

14.2

–

27.5

–

rs4821480

TT

179

15.3

–

13.6

–

26.6

–

GG + GT

28

10.7

1.51

0.43–5.35

0.774^TTvG

17.8

0.72

0.25–2.08

0.561 ^TTvG

33.0

0.72

0.30–1.73

0.490 ^TTvG